Cardiff Oncology, Inc.
$1.78
▼
-1.86%
2026-04-21 06:13:00
www.cardiffoncology.com
NCM: CRDF
Explore Cardiff Oncology, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$123.06 M
Current Price
$1.78
52W High / Low
$4.55 / $1.48
Stock P/E
—
Book Value
$0.66
Dividend Yield
—
ROCE
-107.63%
ROE
-71.45%
Face Value
—
EPS
$-0.69
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
30
Beta
1.42
Debt / Equity
1.83
Current Ratio
3.67
Quick Ratio
3.67
Forward P/E
-2.26
Price / Sales
182.15
Enterprise Value
$50.54 M
EV / EBITDA
-1.04
EV / Revenue
85.24
Rating
Strong Buy
Target Price
$7.75
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Daré Bioscience, Inc. | $2.87 | — | $41.79 M | — | -154.2% | 845.53% | $9.19 / $1.27 | $0.2 |
| 2. | Travere Therapeutics, Inc. | $40.29 | — | $3.72 B | — | -14.11% | -57.8% | $43.31 / $13.88 | $1.26 |
| 3. | TScan Therapeutics, Inc. | $1.43 | — | $67.71 M | — | -64.64% | -71.28% | $2.57 / $0.88 | $2.16 |
| 4. | uniQure N.V. | $18.04 | — | $1.07 B | — | -24.65% | -2.07% | $71.5 / $8.73 | $3.19 |
| 5. | Minerva Neurosciences, Inc. | $6.89 | — | $289.51 M | — | -15.79% | 352.58% | $12.46 / $1.3 | $-3.25 |
| 6. | Corvus Pharmaceuticals, Inc. | $15.54 | — | $1.31 B | — | -69.6% | -32.6% | $26.95 / $3.11 | $0.82 |
| 7. | Prothena Corporation plc | $10.79 | — | $583.55 M | — | -64.54% | -63.62% | $11.69 / $4.32 | $5.21 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.24 M | 0.12 M | 0.12 M | 0.11 M | 0.15 M | — |
| Operating Profit | -7.83 M | -11.97 M | -14.78 M | -14.38 M | -12.57 M | — |
| Net Profit | -7.22 M | -11.26 M | -13.94 M | -13.43 M | -11.79 M | — |
| EPS in Rs | -0.11 | -0.16 | -0.2 | -0.2 | -0.17 | -0.25 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.59 M | 0.68 M | 0.49 M | 0.39 M |
| Operating Profit | -48.96 M | -48.65 M | -45.41 M | -39.9 M |
| Net Profit | -45.85 M | -45.43 M | -41.44 M | -38.7 M |
| EPS in Rs | -0.67 | -0.66 | -0.61 | -0.57 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 61.88 M | 97.19 M | 81.64 M | 116.19 M |
| Total Liabilities | 16.5 M | 14.24 M | 11.9 M | 9.85 M |
| Equity | 45.39 M | 82.95 M | 69.74 M | 106.34 M |
| Current Assets | 60.13 M | 95.05 M | 77.41 M | 111.28 M |
| Current Liabilities | 16.39 M | 13.43 M | 10.44 M | 7.81 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -37.92 M | -37.69 M | -30.89 M | -33.82 M |
| Investing CF | 1.34 M | 13.73 M | 36.2 M | 38.15 M |
| Financing CF | 2.58 M | 53.78 M | 0 M | 0.07 M |
| Free CF | -37.97 M | -37.77 M | -31.47 M | -34.83 M |
| Capex | -0.04 M | -0.08 M | -0.58 M | -1.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 39.96% | 26.42% | — | — |
| Earnings Growth % | -9.63% | -7.07% | — | — |
| Profit Margin % | -6651.68% | -8492.01% | -10026.94% | — |
| Operating Margin % | -7123.13% | -9305.74% | -10337.31% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -6985.07% | -9224.18% | -10276.17% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.